@JH888 biotech is all about risk reward ‘speculation’ pre approval. NTA doesn’t really work for biotech going through the development phase. You need to look at the potential end game, comparative sales and rNPV and gauge the likelihood of success v failure based on your risk profile.
consider how this rates for Bisantrene that was previously approved and the benefits of the historical trial data?
@JH888 biotech is all about risk reward ‘speculation’ pre...
-
- There are more pages in this discussion • 3,656 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.43 |
Change
0.025(1.78%) |
Mkt cap ! $243.6M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.41 | $106.3K | 74.77K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3388 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 4882 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |